JP2017113028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017113028A5 JP2017113028A5 JP2017040585A JP2017040585A JP2017113028A5 JP 2017113028 A5 JP2017113028 A5 JP 2017113028A5 JP 2017040585 A JP2017040585 A JP 2017040585A JP 2017040585 A JP2017040585 A JP 2017040585A JP 2017113028 A5 JP2017113028 A5 JP 2017113028A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- seq
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 17
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 101100440311 Homo sapiens C5 gene Proteins 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019098449A JP7450344B2 (ja) | 2014-03-07 | 2019-05-27 | 向上した薬物動態を有する抗ｃ５抗体 |
| JP2024011008A JP2024038502A (ja) | 2014-03-07 | 2024-01-29 | 向上した薬物動態を有する抗ｃ５抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461949932P | 2014-03-07 | 2014-03-07 | |
| US61/949,932 | 2014-03-07 | ||
| JP2016555463A JP6112469B1 (ja) | 2014-03-07 | 2015-03-06 | 向上した薬物動態を有する抗ｃ５抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555463A Division JP6112469B1 (ja) | 2014-03-07 | 2015-03-06 | 向上した薬物動態を有する抗ｃ５抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019098449A Division JP7450344B2 (ja) | 2014-03-07 | 2019-05-27 | 向上した薬物動態を有する抗ｃ５抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017113028A JP2017113028A (ja) | 2017-06-29 |
| JP2017113028A5 true JP2017113028A5 (enExample) | 2018-03-29 |
| JP6894265B2 JP6894265B2 (ja) | 2021-06-30 |
Family
ID=52684742
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555463A Active JP6112469B1 (ja) | 2014-03-07 | 2015-03-06 | 向上した薬物動態を有する抗ｃ５抗体 |
| JP2017040585A Active JP6894265B2 (ja) | 2014-03-07 | 2017-03-03 | 向上した薬物動態を有する抗ｃ５抗体 |
| JP2019098449A Active JP7450344B2 (ja) | 2014-03-07 | 2019-05-27 | 向上した薬物動態を有する抗ｃ５抗体 |
| JP2020173023A Pending JP2021036870A (ja) | 2014-03-07 | 2020-10-14 | 向上した薬物動態を有する抗ｃ５抗体 |
| JP2024011008A Pending JP2024038502A (ja) | 2014-03-07 | 2024-01-29 | 向上した薬物動態を有する抗ｃ５抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555463A Active JP6112469B1 (ja) | 2014-03-07 | 2015-03-06 | 向上した薬物動態を有する抗ｃ５抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019098449A Active JP7450344B2 (ja) | 2014-03-07 | 2019-05-27 | 向上した薬物動態を有する抗ｃ５抗体 |
| JP2020173023A Pending JP2021036870A (ja) | 2014-03-07 | 2020-10-14 | 向上した薬物動態を有する抗ｃ５抗体 |
| JP2024011008A Pending JP2024038502A (ja) | 2014-03-07 | 2024-01-29 | 向上した薬物動態を有する抗ｃ５抗体 |
Country Status (28)
| Country | Link |
|---|---|
| US (11) | US9079949B1 (enExample) |
| EP (3) | EP3095795B1 (enExample) |
| JP (5) | JP6112469B1 (enExample) |
| KR (4) | KR20230082690A (enExample) |
| CN (2) | CN113416254B (enExample) |
| AR (1) | AR099698A1 (enExample) |
| AU (4) | AU2015226977B2 (enExample) |
| BR (1) | BR112016020454B1 (enExample) |
| CA (2) | CA2942165C (enExample) |
| CY (1) | CY1118018T1 (enExample) |
| DK (2) | DK2970455T3 (enExample) |
| EA (2) | EA035025B1 (enExample) |
| ES (2) | ES2749978T3 (enExample) |
| HR (1) | HRP20161146T1 (enExample) |
| HU (2) | HUE030944T2 (enExample) |
| IL (4) | IL296502A (enExample) |
| LT (1) | LT2970455T (enExample) |
| MA (2) | MA50373A (enExample) |
| ME (1) | ME02629B (enExample) |
| MX (2) | MX368909B (enExample) |
| NZ (2) | NZ711451A (enExample) |
| PL (2) | PL3095795T3 (enExample) |
| PT (2) | PT3095795T (enExample) |
| RS (1) | RS55386B1 (enExample) |
| SI (2) | SI3095795T1 (enExample) |
| SM (1) | SMT201600366B (enExample) |
| TW (4) | TWI667256B (enExample) |
| WO (1) | WO2015134894A1 (enExample) |
Families Citing this family (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| MX336725B (es) | 2007-09-26 | 2016-01-28 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| US20140234340A1 (en) | 2010-11-30 | 2014-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| BR112013021526B1 (pt) | 2011-02-25 | 2021-09-21 | Chugai Seiyaku Kabushiki Kaisha | Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio |
| WO2013002362A1 (ja) | 2011-06-30 | 2013-01-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| CA2857159C (en) | 2011-11-30 | 2024-05-07 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
| EP2813568B1 (en) | 2012-02-09 | 2025-04-23 | Chugai Seiyaku Kabushiki Kaisha | Modified fc region of antibody |
| AU2013222836B2 (en) | 2012-02-20 | 2017-07-20 | Swedish Orphan Biovitrum Ab (Publ) | Polypeptides binding to human complement C5 |
| CN103382223B (zh) * | 2012-04-01 | 2015-06-10 | 上海益杰生物技术有限公司 | 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽 |
| EP2889377B1 (en) | 2012-08-24 | 2020-01-08 | Chugai Seiyaku Kabushiki Kaisha | Fcyriib-specific fc region variant |
| WO2014104165A1 (ja) | 2012-12-27 | 2014-07-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| EP2982689B1 (en) | 2013-04-02 | 2020-08-26 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| EP3210016A1 (en) * | 2014-10-20 | 2017-08-30 | Nestec S.A. | Methods for prediction of anti-tnf alpha drug levels and autoantibody formation |
| US20160168237A1 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
| RS62749B1 (sr) | 2014-12-19 | 2022-01-31 | Chugai Pharmaceutical Co Ltd | Anti-c5 antitela i načini njihove upotrebe |
| NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| CN113956354A (zh) * | 2015-01-22 | 2022-01-21 | 中外制药株式会社 | 两种以上抗-c5抗体的组合与使用方法 |
| CA2974547A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof |
| JP6130983B2 (ja) | 2015-02-27 | 2017-05-17 | 中外製薬株式会社 | Ｉｌ−６関連疾患治療用組成物 |
| WO2016154290A1 (en) * | 2015-03-23 | 2016-09-29 | Alexion Pharmaceuticals, Inc. | Virus filtration |
| WO2016160756A2 (en) | 2015-03-31 | 2016-10-06 | Alexion Pharmaceuticlas, Inc. | Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patents |
| US20180311299A1 (en) | 2015-05-01 | 2018-11-01 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
| EP3302652B1 (en) | 2015-06-04 | 2023-09-06 | Medimop Medical Projects Ltd. | Cartridge insertion for drug delivery device |
| EP3328885A1 (en) | 2015-09-11 | 2018-06-06 | Bruce Andrien | Recombinant glycosylated eculizumab and eculizumab variants |
| CA2997745A1 (en) | 2015-09-14 | 2017-03-23 | Children's Hospital Medical Center | Methods and compositions for treatment of gaucher disease via modulation of c5a receptor |
| US11903994B2 (en) | 2015-10-07 | 2024-02-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
| EP3359566A1 (en) | 2015-10-07 | 2018-08-15 | Alexion Pharmaceuticals, Inc. | A method for treating age-related macular degeneration in a patient |
| US20180311345A1 (en) * | 2015-10-30 | 2018-11-01 | Alexion Pharmaceuticals, Inc. | A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy |
| SG10201709415WA (en) | 2015-12-18 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| US20200270363A1 (en) * | 2015-12-25 | 2020-08-27 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| WO2017123636A1 (en) | 2016-01-11 | 2017-07-20 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| WO2017132259A1 (en) * | 2016-01-25 | 2017-08-03 | Shire Human Genetic Therapies, Inc. | Anti-c5 antibodies with enhanced ph switch |
| PL234632B1 (pl) | 2016-03-02 | 2020-03-31 | Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk | Przeciwciała oddziałujące z komórkami psich chłoniaków typu B i ich zastosowania |
| MA44780A (fr) | 2016-04-28 | 2019-03-06 | Chugai Pharmaceutical Co Ltd | Préparation contenant un anticorps |
| EP3463461A4 (en) | 2016-05-27 | 2020-05-20 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| CN109310760A (zh) | 2016-06-07 | 2019-02-05 | 诺华股份有限公司 | 抗c5抗体给药方案 |
| JP7102353B2 (ja) | 2016-06-14 | 2022-07-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｃ５抗体及びそれらの使用 |
| TWI789369B (zh) * | 2016-06-17 | 2023-01-11 | 日商中外製藥股份有限公司 | 抗ｃ５抗體及使用方法 |
| IL264626B (en) | 2016-08-05 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Composition for prophylaxis or treatment of il-8 related diseases |
| US20190276524A1 (en) | 2016-10-12 | 2019-09-12 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
| ES2848206T3 (es) | 2016-10-19 | 2021-08-05 | Alexion Pharma Inc | Un método de cuantificar C5 sin unir en una muestra |
| JP7128182B2 (ja) | 2016-10-27 | 2022-08-30 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体関連障害におけるＣ５ｂ－９沈着に関するアッセイ |
| KR102579940B1 (ko) * | 2016-12-16 | 2023-09-15 | 삼성바이오에피스 주식회사 | 안정한 액상의 항-c5 항체 조성물 |
| EP3574010A4 (en) | 2017-01-30 | 2020-12-16 | Chugai Seiyaku Kabushiki Kaisha | ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE |
| KR101949891B1 (ko) * | 2017-01-31 | 2019-02-19 | 추가이 세이야쿠 가부시키가이샤 | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 |
| CN110603054B (zh) * | 2017-03-06 | 2024-05-10 | 宾夕法尼亚大学理事会 | 抗c5抗体及其用途 |
| EP3601336B1 (en) | 2017-03-31 | 2024-08-28 | Alexion Pharmaceuticals, Inc. | Method for simultaneous quantification of alxn1210 and eculizumab in human serum or urine |
| KR20190139931A (ko) | 2017-04-07 | 2019-12-18 | 아펠리스 파마슈티컬스 인코포레이티드 | 투여 요법 및 관련 조성물 및 방법 |
| WO2018195034A1 (en) | 2017-04-19 | 2018-10-25 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
| US11643473B2 (en) | 2017-04-24 | 2023-05-09 | Alexion Pharmaceuticals, Inc. | Antibody immune cell inhibitor fusion proteins |
| WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| JP7325339B2 (ja) * | 2017-05-30 | 2023-08-14 | チョン クン ダン ファーマシューティカル コーポレーション | 新規な抗ｃ－Ｍｅｔ抗体およびその用途 |
| JP7684803B2 (ja) | 2017-07-11 | 2025-05-28 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
| EP3658184B1 (en) * | 2017-07-27 | 2023-09-06 | Alexion Pharmaceuticals, Inc. | High concentration anti-c5 antibody formulations |
| EP4424324A3 (en) | 2017-10-04 | 2024-11-06 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis |
| US12128101B2 (en) | 2017-10-26 | 2024-10-29 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) |
| IL274265B1 (en) | 2017-11-01 | 2025-09-01 | Chugai Pharmaceutical Co Ltd | Variant and isoform of an antibody with attenuated biological activity |
| JP7731196B2 (ja) | 2017-11-14 | 2025-08-29 | 中外製薬株式会社 | 抗Ｃ１ｓ抗体および使用方法 |
| CA3084043A1 (en) * | 2017-12-04 | 2019-06-13 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| CN111630065A (zh) | 2017-12-13 | 2020-09-04 | 瑞泽恩制药公司 | 抗c5抗体组合及其用途 |
| KR20240167712A (ko) | 2017-12-15 | 2024-11-27 | 아펠리스 파마슈티컬스 인코포레이티드 | 투여 요법 및 관련 조성물 및 방법 |
| CN111683703B (zh) | 2017-12-22 | 2022-11-18 | 西氏医药包装(以色列)有限公司 | 适用于不同尺寸的药筒的注射器 |
| WO2019143761A1 (en) * | 2018-01-17 | 2019-07-25 | Children's Hospital Medical Center | Compositions and methods for treatment of hunter's syndrome |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| EP3802593B1 (en) * | 2018-05-31 | 2024-09-11 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| JP7577542B2 (ja) | 2018-06-04 | 2024-11-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与 |
| KR20210035173A (ko) * | 2018-06-19 | 2021-03-31 | 아타르가, 엘엘씨 | 보체 성분 5에 대한 항체분자 및 이의 용도 |
| US12312394B2 (en) | 2018-06-28 | 2025-05-27 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-C5 antibodies |
| WO2020032230A1 (ja) | 2018-08-10 | 2020-02-13 | 中外製薬株式会社 | 抗ｃｄ１３７抗原結合分子およびその使用 |
| WO2020041301A1 (en) | 2018-08-20 | 2020-02-27 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| KR20210055742A (ko) * | 2018-09-06 | 2021-05-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 인간화된 항-c5 항체 및 이의 용도 |
| EP3846803A4 (en) | 2018-09-06 | 2022-08-10 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| EP3852874A1 (en) | 2018-09-17 | 2021-07-28 | Kyoto University | Administration of an anti-c5 agent for treatment of hepatic injury or failure |
| US20200095307A1 (en) | 2018-09-21 | 2020-03-26 | Alexion Pharmaceuticals, Inc. | Compositions and methods for the treatment of neuromyelitis optica |
| WO2020077169A1 (en) * | 2018-10-12 | 2020-04-16 | Trican Biotechnology Co., Ltd | Bi-functional fusion proteins and uses thereof |
| WO2020092546A1 (en) | 2018-10-30 | 2020-05-07 | Alexion Pharmaceuticals, Inc. | Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions |
| CN119405797A (zh) | 2018-10-30 | 2025-02-11 | 亚力兄制药公司 | 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用 |
| WO2020106724A1 (en) | 2018-11-20 | 2020-05-28 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis in pediatric patients |
| CN117838856A (zh) | 2019-01-25 | 2024-04-09 | 亚力兄制药公司 | 用于治疗非典型溶血性尿毒综合征(ahus)的抗c5抗体的剂量和施用 |
| US11642470B2 (en) * | 2019-02-11 | 2023-05-09 | West Pharma. Services IL, Ltd. | Anti-C5 antibody dispensing injector and method of injection |
| EP3924380A1 (en) | 2019-02-14 | 2021-12-22 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis |
| EP3958901A4 (en) * | 2019-04-24 | 2023-07-19 | The Trustees of the University of Pennsylvania | BI-FUNCTIONAL HUMANIZED ANTI-C5 ANTIBODIES AND H-FACTOR FUSION PROTEINS AND THEIR USES |
| US12473353B2 (en) | 2019-05-15 | 2025-11-18 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule, a pharmaceutical composition, and a method |
| WO2020242849A1 (en) | 2019-05-24 | 2020-12-03 | Alexion Pharmaceuticals, Inc. | Methods of treating vitiligo using an anti-c5 antibody |
| CA3140193A1 (en) * | 2019-06-04 | 2020-12-10 | Ra Pharmaceuticals, Inc. | Inflammatory disease treatment with complement inhibitors |
| WO2021026160A1 (en) | 2019-08-05 | 2021-02-11 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis with eculizumab |
| WO2021067526A1 (en) | 2019-10-02 | 2021-04-08 | Alexion Pharmaceuticals, Inc. | Complement inhibitors for treating drug-induced complement-mediated response |
| WO2021091937A1 (en) | 2019-11-08 | 2021-05-14 | Alexion Pharmaceuticals, Inc. | High concentration anti-c5 antibody formulations |
| MX2022007116A (es) | 2019-12-09 | 2022-07-11 | Alexion Pharma Inc | Anticuerpo anti-c5 para el tratamiento del trastorno del espectro de la neuromielitis optica. |
| JP7734673B2 (ja) | 2019-12-23 | 2025-09-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｃ５抗体を使用して妊娠関連非典型溶血性尿毒症症候群を治療する方法 |
| US20250197403A1 (en) | 2020-02-20 | 2025-06-19 | Achillion Pharmaceuticals, Inc. | Heteroaryl compounds for treatment of complement factor d mediated disorders |
| JP2023522208A (ja) | 2020-04-16 | 2023-05-29 | アシスタンス ピュブリック－オピト ド パリ | ウイルスによって引き起こされる補体媒介性障害を処置する方法 |
| CA3181198A1 (en) | 2020-04-30 | 2021-11-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
| EP4149473A1 (en) | 2020-05-12 | 2023-03-22 | Alexion Pharmaceuticals, Inc. | Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria |
| US20230349887A1 (en) | 2020-05-15 | 2023-11-02 | Alexion Pharmaceuticals, Inc. | Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease |
| CN113754763B (zh) * | 2020-06-05 | 2024-03-08 | 天辰生物医药(苏州)有限公司 | 分离的抗原结合蛋白及其用途 |
| CN116194478A (zh) | 2020-06-24 | 2023-05-30 | 阿雷克森制药公司 | 皮下（sc）施用抗c5抗体治疗补体相关病症 |
| WO2021263056A1 (en) * | 2020-06-25 | 2021-12-30 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of amyotrophic lateral sclerosis |
| JP2023533030A (ja) | 2020-07-09 | 2023-08-01 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者において発作性夜間血色素尿症（ｐｎｈ）を治療するための抗ｃ５抗体の投薬量及び投与 |
| US20240209071A1 (en) | 2020-08-13 | 2024-06-27 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
| KR20230073261A (ko) | 2020-09-21 | 2023-05-25 | 알렉시온 파마슈티칼스, 인코포레이티드 | 루푸스 신장염(ln) 및/또는 iga 신장병(igan)을 포함하는, c5-매개 사구체 신장염(gn)을 치료하기 위한 항-c5 항체의 투여량 및 투여 |
| CA3193488A1 (en) | 2020-09-23 | 2022-03-31 | Jason Allan Wiles | Pharmaceutical compounds for the treatment of complement mediated disorders |
| JP2023548046A (ja) | 2020-10-23 | 2023-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｃ５抗体を使用する、補体障害を有する患者の処置方法 |
| US12103961B2 (en) * | 2020-12-07 | 2024-10-01 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use |
| CN114149501B (zh) * | 2020-12-11 | 2023-05-26 | 天士力生物医药股份有限公司 | 抗c5抗体及其应用 |
| CN117042798A (zh) * | 2020-12-25 | 2023-11-10 | 宾夕法尼亚大学理事会 | 人源化抗-c5抗体和因子h融合蛋白及其用途 |
| CA3173016A1 (en) | 2021-01-22 | 2022-07-28 | Gin-Fu CHEN | Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody |
| CA3220629A1 (en) | 2021-05-28 | 2022-12-01 | Tobin J. CAMMETT | Methods for detecting cm-tma biomarkers |
| WO2022265915A1 (en) | 2021-06-14 | 2022-12-22 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating dermatomyositis (dm) |
| EP4370547A1 (en) | 2021-07-14 | 2024-05-22 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis |
| WO2023023220A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor |
| US20230203176A1 (en) | 2021-09-17 | 2023-06-29 | Novartis Ag | Methods For Prevention Of Graft Rejection In Xenotransplantation |
| CN118302525A (zh) | 2021-10-29 | 2024-07-05 | 阿尔尼拉姆医药品有限公司 | 补体因子B（CFB）iRNA组合物及其使用方法 |
| EP4426348A4 (en) * | 2021-11-01 | 2025-10-01 | Ipc Res Llc | ADMINISTRATION OF C5-BINDING PROTEINS |
| TW202426048A (zh) | 2022-09-06 | 2024-07-01 | 美商阿雷希昂製藥公司 | 用於治療造血幹細胞移植相關血栓性（ｈｓｃｔ－ｔｍａ）的抗ｃ５抗體的補充劑量和投與 |
| CA3266977A1 (en) | 2022-09-06 | 2024-03-14 | Alexion Pharmaceuticals, Inc. | DIAGNOSTIC AND PROGNOSIS BIOMARKER PROFILES IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) |
| TW202423479A (zh) | 2022-09-28 | 2024-06-16 | 美商阿雷希昂製藥公司 | 用於預防或最小化患有慢性腎病的患者中的心臟手術相關急性腎損傷（csa-aki）和/或隨後的主要不良腎事件（make）的抗c5抗體之劑量及投與 |
| WO2024238421A1 (en) | 2023-05-12 | 2024-11-21 | Alexion Pharmaceuticals, Inc. | Use of biomarkers for the identification and treatment of complement-mediated disorders |
| WO2024238422A1 (en) | 2023-05-12 | 2024-11-21 | Alexion Pharmaceuticals, Inc. | Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles |
| CN116712390B (zh) * | 2023-08-04 | 2023-11-14 | 上海览屹医药科技有限公司 | 一种高浓度高稳定性的抗体制剂及其制备方法 |
| WO2025045250A1 (en) | 2023-09-03 | 2025-03-06 | Kira Pharmaceuticals (Us) Llc | Anti-human factor d antibody constructs and uses thereof |
| WO2025166118A1 (en) | 2024-02-02 | 2025-08-07 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan) |
| WO2025199107A1 (en) | 2024-03-19 | 2025-09-25 | Alexion Pharmaceuticals, Inc. | Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor |
| WO2025221479A1 (en) | 2024-04-16 | 2025-10-23 | Alexion Pharmaceuticals, Inc. | Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) with complement component c5 inhibitors |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| EP0228458B2 (en) | 1985-07-05 | 1997-10-22 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
| ES2054667T3 (es) * | 1986-04-28 | 1994-08-16 | Cetus Oncology Corp | Anticuerpos monoclonales contra c5a y des-arg74-c5a, su produccion y uso. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| EP0633318A1 (en) | 1987-09-11 | 1995-01-11 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
| JP2914692B2 (ja) | 1987-12-11 | 1999-07-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 内皮細胞の遺伝子修飾 |
| DE68927996T2 (de) | 1988-02-05 | 1997-12-04 | Hughes Howard Med Inst | Modifizierte hepatozyten und deren anwendung |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| ES2115662T3 (es) | 1990-10-31 | 1998-07-01 | Cell Genesys Inc | Modificacion genetica de celulas endoteliales. |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| GB9026191D0 (en) | 1990-12-01 | 1991-01-16 | Harris Pharma Ltd | Breath actuated dispensing device |
| JPH07503124A (ja) | 1991-06-14 | 1995-04-06 | ゾーマ・コーポレーション | 微生物によって生産される抗体断片とそれらの複合体 |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| DE69318409T2 (de) | 1992-07-23 | 1998-12-03 | Minnesota Mining And Mfg. Co., Saint Paul, Minn. | Geformte schleifteilchen und verfahren zur ihrer herstellung |
| ES2338321T3 (es) | 1992-08-21 | 2010-05-06 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever N.V., Rotterdam | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| IT1265573B1 (it) | 1993-09-17 | 1996-11-22 | Zanussi Grandi Impianti Spa | Forno di cottura di alimenti con porta perfezionata |
| US5308341A (en) | 1993-09-28 | 1994-05-03 | Becton, Dickinson And Company | Method of testing the dose accuracy of a medication delivery device |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| HUT75676A (en) | 1994-03-07 | 1997-05-28 | Inhale Therapeutic Syst | Methods and compositions for pulmonary delivery of insulin |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| DE69621940T2 (de) | 1995-08-18 | 2003-01-16 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO1997042217A1 (en) | 1996-05-06 | 1997-11-13 | The Uab Research Foundation | Radiolabeled fusion toxins for cancer therapy |
| US6146361A (en) | 1996-09-26 | 2000-11-14 | Becton Dickinson And Company | Medication delivery pen having a 31 gauge needle |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| GB9626960D0 (en) | 1996-12-27 | 1997-02-12 | Glaxo Group Ltd | Valve for aerosol container |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| AU7467898A (en) | 1997-04-21 | 1998-11-13 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy |
| NZ504021A (en) | 1997-10-17 | 2003-04-29 | Systemic Pulmonary Delivery Lt | Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication |
| AU3369999A (en) | 1998-04-02 | 1999-10-25 | Genentech Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| NZ539776A (en) | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
| JP2002541213A (ja) | 1999-04-13 | 2002-12-03 | インヘール セラピューティック システムズ， インコーポレイテッド | 不妊症の処置のための乾燥粉末処方物の肺投与 |
| WO2000061178A1 (en) | 1999-04-13 | 2000-10-19 | Inhale Therapeutics Systems, Inc. | Pulmonary administration of dry powder formulations for treating infertility |
| US6192891B1 (en) | 1999-04-26 | 2001-02-27 | Becton Dickinson And Company | Integrated system including medication delivery pen, blood monitoring device, and lancer |
| GB9910975D0 (en) | 1999-05-13 | 1999-07-14 | Univ Strathclyde | Rapid dehydration of proteins |
| US6277099B1 (en) | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| PT1313415E (pt) | 2000-08-30 | 2008-11-25 | Univ Johns Hopkins | Dispositivos para entrega intra-ocular de fármacos |
| CA2431600C (en) | 2000-12-12 | 2012-04-17 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| CN100391537C (zh) * | 2001-08-17 | 2008-06-04 | 建南德克公司 | 结合至c5和c5a但不阻止c5b形成的补体途径抑制剂 |
| MXPA04002283A (es) | 2001-09-12 | 2004-06-29 | Becton Dickinson Co | Dispositivo de pluma a base de microaguja para el suministro de farmaco y metodo para utilizar el mismo. |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| US20060141456A1 (en) | 2002-06-12 | 2006-06-29 | Cynthia Edwards | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| US20040102469A1 (en) | 2002-09-13 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for reducing the mortality rate |
| GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
| CN101987871A (zh) | 2002-09-27 | 2011-03-23 | 赞科股份有限公司 | 优化的Fc变体及其产生方法 |
| FR2849436B1 (fr) | 2002-12-27 | 2007-01-05 | Patrick Frayssinet | Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro |
| WO2004073551A2 (en) | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Transscleral drug delivery device and related methods |
| EP1648511A1 (en) | 2003-07-29 | 2006-04-26 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| US20070148170A1 (en) | 2005-10-03 | 2007-06-28 | Desjarlais John R | Fc Variants With Optimized Fc Receptor Binding Properties |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| GB0416328D0 (en) | 2004-07-21 | 2004-08-25 | Univ Cardiff | Use of dry powder compositions for pulmonary delivery |
| US20060074225A1 (en) | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006094234A1 (en) | 2005-03-03 | 2006-09-08 | Xencor, Inc. | Methods for the design of libraries of protein variants |
| WO2006105338A2 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| AU2006330858A1 (en) | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
| US20100135992A1 (en) | 2006-03-02 | 2010-06-03 | Alexion Pharmaceuticals, Inc. | Prolongation of Survival of an Allograft by Inhibiting Complement Activity |
| JP2009530299A (ja) * | 2006-03-15 | 2009-08-27 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| US8037880B2 (en) | 2006-04-07 | 2011-10-18 | The University Of Western Ontario | Dry powder inhaler |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| WO2008048545A2 (en) | 2006-10-16 | 2008-04-24 | Medimmune, Llc. | Molecules with reduced half-lives, compositions and uses thereof |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| EP2173380A4 (en) | 2007-07-13 | 2011-08-31 | Abbott Biotech Ltd | METHOD AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa HEMMER |
| MX336725B (es) | 2007-09-26 | 2016-01-28 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
| CA2703997C (en) | 2007-12-26 | 2017-04-04 | Xencor, Inc. | Fc variants with altered binding to fcrn |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| AU2009303526B2 (en) | 2008-10-14 | 2015-01-15 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| KR20110094029A (ko) * | 2008-11-10 | 2011-08-19 | 알렉시온 파마슈티칼스, 인코포레이티드 | 보체-관련된 장애를 치료하는 방법 및 조성물 |
| US8775090B2 (en) * | 2008-12-12 | 2014-07-08 | Medimmune, Llc | Crystals and structure of a human IgG Fc variant with enhanced FcRn binding |
| JP2012531418A (ja) * | 2009-06-23 | 2012-12-10 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体タンパク質に結合する二重特異性抗体 |
| CA2795311A1 (en) * | 2009-11-05 | 2011-05-12 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| CN105218674A (zh) * | 2010-03-11 | 2016-01-06 | 瑞纳神经科学公司 | 呈pH依赖性抗原结合的抗体 |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| EP2563813B1 (en) * | 2010-04-30 | 2015-08-26 | Alexion Pharmaceuticals, Inc. | Anti-c5a antibodies and methods for using the antibodies |
| EP2563812A4 (en) | 2010-04-30 | 2016-01-13 | Alexion Pharma Inc | ANTIBODIES WITH REDUCED IMMUNOGENITY IN HUMANS |
| US20140234340A1 (en) | 2010-11-30 | 2014-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| CA2822288A1 (en) * | 2010-12-22 | 2012-06-28 | Medimmune, Llc | Anti-c5/c5a/c5adesr antibodies and fragments |
| WO2012133782A1 (ja) | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| CA2871934C (en) * | 2012-04-30 | 2023-06-13 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| WO2016160756A2 (en) | 2015-03-31 | 2016-10-06 | Alexion Pharmaceuticlas, Inc. | Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patents |
| US20180311299A1 (en) | 2015-05-01 | 2018-11-01 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
| US20180311345A1 (en) | 2015-10-30 | 2018-11-01 | Alexion Pharmaceuticals, Inc. | A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy |
| JP7102353B2 (ja) * | 2016-06-14 | 2022-07-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｃ５抗体及びそれらの使用 |
| US20190276524A1 (en) | 2016-10-12 | 2019-09-12 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
-
2014
- 2014-09-11 NZ NZ711451A patent/NZ711451A/en unknown
- 2014-09-11 NZ NZ631007A patent/NZ631007A/en unknown
-
2015
- 2015-03-06 EP EP16177656.2A patent/EP3095795B1/en active Active
- 2015-03-06 PL PL16177656T patent/PL3095795T3/pl unknown
- 2015-03-06 IL IL296502A patent/IL296502A/en unknown
- 2015-03-06 CA CA2942165A patent/CA2942165C/en active Active
- 2015-03-06 SI SI201530940T patent/SI3095795T1/sl unknown
- 2015-03-06 KR KR1020237018254A patent/KR20230082690A/ko active Pending
- 2015-03-06 WO PCT/US2015/019225 patent/WO2015134894A1/en not_active Ceased
- 2015-03-06 PT PT161776562T patent/PT3095795T/pt unknown
- 2015-03-06 CN CN202110517494.0A patent/CN113416254B/zh active Active
- 2015-03-06 CN CN201580012081.XA patent/CN106459189B/zh active Active
- 2015-03-06 EA EA201691764A patent/EA035025B1/ru unknown
- 2015-03-06 TW TW104107187A patent/TWI667256B/zh active
- 2015-03-06 RS RS20160996A patent/RS55386B1/sr unknown
- 2015-03-06 MA MA050373A patent/MA50373A/fr unknown
- 2015-03-06 PT PT157103961T patent/PT2970455T/pt unknown
- 2015-03-06 ES ES16177656T patent/ES2749978T3/es active Active
- 2015-03-06 MA MA38859A patent/MA38859B1/fr unknown
- 2015-03-06 EP EP15710396.1A patent/EP2970455B1/en active Active
- 2015-03-06 ME MEP-2016-264A patent/ME02629B/me unknown
- 2015-03-06 EP EP19176561.9A patent/EP3594235A1/en active Pending
- 2015-03-06 KR KR1020177032026A patent/KR102304136B1/ko active Active
- 2015-03-06 KR KR1020167027411A patent/KR101796886B1/ko active Active
- 2015-03-06 ES ES15710396.1T patent/ES2589230T3/es active Active
- 2015-03-06 CA CA3166772A patent/CA3166772A1/en active Pending
- 2015-03-06 KR KR1020217011897A patent/KR102539636B1/ko active Active
- 2015-03-06 HU HUE15710396A patent/HUE030944T2/en unknown
- 2015-03-06 BR BR112016020454-9A patent/BR112016020454B1/pt active IP Right Grant
- 2015-03-06 EA EA202090275A patent/EA202090275A3/ru unknown
- 2015-03-06 TW TW108122663A patent/TWI708785B/zh active
- 2015-03-06 JP JP2016555463A patent/JP6112469B1/ja active Active
- 2015-03-06 US US14/641,026 patent/US9079949B1/en active Active
- 2015-03-06 HU HUE16177656A patent/HUE046091T2/hu unknown
- 2015-03-06 LT LTEP15710396.1T patent/LT2970455T/lt unknown
- 2015-03-06 TW TW109133882A patent/TWI845769B/zh active
- 2015-03-06 PL PL15710396T patent/PL2970455T3/pl unknown
- 2015-03-06 MX MX2016011628A patent/MX368909B/es active IP Right Grant
- 2015-03-06 HR HRP20161146TT patent/HRP20161146T1/hr unknown
- 2015-03-06 DK DK15710396.1T patent/DK2970455T3/en active
- 2015-03-06 TW TW113129415A patent/TW202446794A/zh unknown
- 2015-03-06 DK DK16177656.2T patent/DK3095795T3/da active
- 2015-03-06 AU AU2015226977A patent/AU2015226977B2/en active Active
- 2015-03-06 AR ARP150100697A patent/AR099698A1/es active IP Right Grant
- 2015-03-06 SI SI201530009A patent/SI2970455T1/sl unknown
- 2015-06-01 US US14/727,313 patent/US9107861B1/en active Active
- 2015-07-01 US US14/789,329 patent/US9206251B2/en active Active
- 2015-10-27 US US14/923,879 patent/US9371377B2/en active Active
-
2016
- 2016-05-20 US US15/160,364 patent/US9663574B2/en active Active
- 2016-08-17 IL IL247331A patent/IL247331B/en active IP Right Grant
- 2016-09-07 MX MX2019012455A patent/MX2019012455A/es unknown
- 2016-09-16 CY CY20161100922T patent/CY1118018T1/el unknown
- 2016-10-12 SM SM201600366T patent/SMT201600366B/it unknown
-
2017
- 2017-03-03 JP JP2017040585A patent/JP6894265B2/ja active Active
- 2017-04-20 US US15/492,622 patent/US9803007B1/en active Active
- 2017-09-19 US US15/708,658 patent/US10227400B2/en active Active
-
2019
- 2019-01-14 US US16/246,842 patent/US10584164B2/en active Active
- 2019-05-27 JP JP2019098449A patent/JP7450344B2/ja active Active
- 2019-09-24 AU AU2019236617A patent/AU2019236617B2/en active Active
-
2020
- 2020-01-23 US US16/750,173 patent/US11434280B2/en active Active
- 2020-03-17 IL IL273337A patent/IL273337B/en unknown
- 2020-10-14 JP JP2020173023A patent/JP2021036870A/ja active Pending
- 2020-11-16 AU AU2020267324A patent/AU2020267324B2/en active Active
-
2021
- 2021-11-15 IL IL288139A patent/IL288139A/en unknown
-
2023
- 2023-07-07 US US18/219,138 patent/US20240141024A1/en active Pending
-
2024
- 2024-01-29 JP JP2024011008A patent/JP2024038502A/ja active Pending
- 2024-07-16 AU AU2024204884A patent/AU2024204884A1/en active Pending
-
2025
- 2025-01-09 US US19/014,615 patent/US20250145698A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017113028A5 (enExample) | ||
| CN104774266B (zh) | 白介素-13结合蛋白 | |
| JP2020500538A5 (enExample) | ||
| JP2018521638A5 (enExample) | ||
| JP2019502712A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| JP2019536806A5 (enExample) | ||
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| JP2017536341A5 (enExample) | ||
| JP2017523786A5 (enExample) | ||
| JP2016529229A5 (enExample) | ||
| TW201124427A (en) | IL-1 binding proteins | |
| AU2021221287B2 (en) | Engineered anti-IL-2 antibodies | |
| JP2013538057A5 (enExample) | ||
| JP2017534577A5 (enExample) | ||
| JP2011528901A5 (enExample) | ||
| JP2017530722A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2016511277A5 (enExample) | ||
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| JP2017500018A5 (enExample) | ||
| PE20210554A1 (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos | |
| JP2012531922A5 (ja) | Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位 | |
| PE20221585A1 (es) | Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla-4) y uso del mismo | |
| JP2019509054A5 (enExample) |